First Tracks Biotherapeutics posted "impressive" results for its celiac disease treatment Monday, and the IPO stock surged.
Yahoo
Skip to navigation
Skip to main content
Skip to right column
Why This IPO Stock, An AnaptysBio Spinoff, Just Surged ·
Investor's Business Daily
